EP1384775B1 - Somatic pluripotent cells - Google Patents
Somatic pluripotent cells Download PDFInfo
- Publication number
- EP1384775B1 EP1384775B1 EP02257930A EP02257930A EP1384775B1 EP 1384775 B1 EP1384775 B1 EP 1384775B1 EP 02257930 A EP02257930 A EP 02257930A EP 02257930 A EP02257930 A EP 02257930A EP 1384775 B1 EP1384775 B1 EP 1384775B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cells
- pluripotent
- cell
- serum
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
- C12N2506/1353—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
- C12N2506/1369—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from blood-borne mesenchymal stem cells, e.g. MSC from umbilical blood
Definitions
- Pluripotent embryonic stem (ES) cells are derived from early mammalian embryos. They can differentiate in vivo into all cell lineages, and, when induced in vitro, differentiate into most cell types. Due to their pluripotency, ES cells are believed to hold a great promise for treating degenerative or inherited diseases. Ethical considerations have hampered the use of human ES cells in research and therapy. Pluripotent cells of a non-embryonic origin (e.g., somatic cells) would circumvent this obstacle.
- WO 02/34890 discloses somatic cells that de-differentiate to give rise to chromosomally normal stem cells (soma-derived ES cells) that express Oct-4 and have the ability to form cells of the mesodermal, endodermal and ectodermal lineages. This is achieved by "abusing" the somatic cells, using conditions unfavourable to their growth (e.g. use of Leukocyte Inhibiting Factor).
- WO 01/21767 discloses that embryonic-like stem cells derived from adult tissue are isolated by freezing and thawing, which is a process derived from the one used for isolation of mesenchymal stem cells. These cells are shown to differentiate into mesenchymal (osteoblast, chrondrocyte, adipocyte, muscle) as well as endodermal (gastro-intestinal epithelium) and ectodermal (neuron, glial, keratinocyte) lineages. The cells are SSEA-1 positive.
- the present invention produces a pluripotent animal cell that has a normal karyotype and is capable, when induced in vitro, of developing into an embryoid body, i.e., a cellular mass that can further develop into structures having features of an organ. Examples of such structures include a primordial gut, exhibiting regular contraction and relaxation.
- the cultured pluripotent cell is somatic since it is of a non-embryonic or non-germ-line origin.
- the invention is also capable of producing an animal cell that has a normal karyotype which is capable of, when introduced into a severely combined immunodeficient (SCID) mouse, developing into a teratoma.
- a teratoma is a tumor containing tissues derived from all three embryonic germ layers, i.e., ectoderm, mesoderm, and endoderm. Examples of the tissues include cornea lens and developing epidermis (ectoderm), cartilage and striated muscle (mesoderm), and liver and gastrointestinal tracts (endoderm).
- the pluripotent cell when induced in vitro, can develop into an embryoid body.
- the cultured cell does not express stage-specific embryonic antigen-1 (SSEA-1), i.e., SSEA-1 negative.
- SSEA-1 stage-specific embryonic antigen-1
- the present invention features a method of producing pluripotent animal cells, such as those described above.
- the method includes (1) culturing mesenchymal stem cells under a starving condition; and (2) identifying and enriching pluripotent cells among the cultured cells.
- the enriched pluripotent cells when introduced into SCID mice, develop into teratomas, and do not express stage-specific embryonic antigen-1 (SSEA-1), i.e. SSEA-1 negative.
- SSEA-1 stage-specific embryonic antigen-1
- the mesenchymal stem cells can be isolated from mammals, including a human. Any suitable tissues can be used to isolate mesenchymal stem cells for use in this method. Examples of such tissues include umbilical cord blood, bone marrow, amniotic fluid, adipose tissue, placenta, and peripheral blood.
- the isolated cells are cultured under a starving condition unfavorable for cells to grow, e.g., in a starving medium containing 0.5% to 2% serum for 5-10 days, or in a regular medium containing 10% to 20% serum for 7 to 21 days without changing the medium.
- a regular medium contains nutrients and factors that promote cell proliferation.
- a starving medium is low in nutrients and factors for cell proliferation.
- the nutrients include serum and serum replacements, and the factors include insulin, epidermal growth factors (EGF), acidic fibroblast growth factors (aFGF), and basic fibroblast growth factors (bFGF).
- EGF epidermal growth factors
- aFGF acidic fibroblast growth factors
- bFGF basic fibroblast growth factors
- pluripotent cells can be identified and enriched based on, for example, their morphology and cell-surface markers (e.g., SSEA-1 negative).
- the present invention relates to culturing mesenchymal stem cells under a starving condition to produce pluripotent cells. These cells are pluripotent since they develop into embryoid bodies when induced in vitro, or develop into teratomas when introduced into SCID mice. The cells have all of the chromosomes, which are characteristic of those in normal cells, and have no noticeable alteration. In other words, they have a normal karyotype.
- the cells have phenotypes characteristic of undifferentiated ES cells. In one example, they spontaneously form flattened spheroid colonies in cultures. Similar colonies have been found in the culture of undifferentiated ES cells. See, e.g., Thomson J. et al., Science, 282:1145-1147, 1998 .
- the cells can also show antigenic properties characteristic of undifferentiated ES cells, e.g., not expressing specific stage embryonic antigen (SSEA)-1, but expressing SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, and Oct-4.
- Oct is a family of transcription factors that are crucial for the development of pluripotent cells. Oct-4, specifically expressed in the mammalian germ line cells and stem cells, is essential for maintaining their pluripotency (see, e.g., Nichols J. et al., Cell, 95:379-391, 1998 ).
- the cells can also have high-level telomerase activity.
- a telomerase is a ribonucleoprotein that adds telomere repeats to the ends of chromosomes during cell duplication, thereby maintaining lengths of telomeres and chromosomes.
- High-level expression of telomerase has been found in germ line cells, ES cells, and embryonic tissues, but not in somatic cells. As a result, telomeres (and chromosomes) become shorter in somatic cells after each cell division. Finally, after a finite life span, somatic cells enter senescence due to loss of chromosomal DNA. As restored telomerase expression in somatic cells extends their life span, the high-level telomerase activity in cells produced by the invention suggests that their life span equals to that of ES cells.
- the method comprises culturing mesenchymal stem cells under a starving condition, and identifying and enriching the cultured cells.
- the pluripotent cells are, therefore, produced from mesenchymal stem cells which can be isolated from, e.g., umbilical cord blood, bone marrow, amniotic fluid, adipose tissue, placenta, or peripheral blood cells using the method described in Example 2 below or analogous methods well known in the art. See, e.g., Erices A. et al., British J. Haematol., 109:235-242, 2000 , Pittenger M. et al., Science, 284:143-147, 1999 , Safford K. et al., Biochem.
- the mesenchymal stem cells can be maintained in an alpha-modified MEM containing 10-20% ES-screened fetal bovine serum (FBS) and bFGF, or cultured under a starving condition described above. Neither cell fusion nor nucleus transferring is required in converting the mesenchymal stem cells to pluripotent cells under the starving condition.
- FBS fetal bovine serum
- bFGF fetal bovine serum
- pluripotent somatic cells can be identified according to their morphology (e.g., cell size and shape), enzymatic activity (e.g., alkaline phosphatase and telomerase), and surface makers (e.g., SSEA-1 negative, SSEA-3 positive, and SSEA-4 positive).
- the identified cells can be enriched using any suitable cell separation techniques known in the art. For example, as cells tend to form colonies, one can directly pick up the colonies using a micropipette under a microscope. To more rapidly enrich a large amount of cells, one can use the fluorescence-activated cell sorting (FACS) techniques.
- FACS fluorescence-activated cell sorting
- anti-SSEA-3 monoclonal antibodies, anti-SSEA-4 monoclonal antibodies, and anti-SSEA-1 monoclonal antibodies linked with different fluorescent labels are used to enrich cells that are SSEA-3 positive, SSEA-4 positive, and SSEA-1 negative. These cells can be further examined for their pluripotency.
- the cells produced by the method of the present invention can be used in a variety of ways.
- mesenchymal stem cells from a patient, e.g., lacking a functional gene essential for proper development of a tissue or organ.
- he or she can introduce into the cells an expression nucleic acid vector encoding a functional version of the gene.
- the vector can be introduced into the cells via a variety of techniques, including calcium phosphate co-precipitation, DEAE-dextran-mediated transfection, lipofection, electroporation, microinjection, or virus-meditated techniques.
- Methods not affecting the pluripotency of the cells are preferred. Description of such techniques can be found in, e.g., United States Patent Application No. 5,591,625 and United States Patent Application NO. 20020127715 .
- the functional gene can be found in, e.g., United States Patent Application No. 5,591,625 and United States Patent Application NO. 20020127715 .
- the treatment does not cause immune rejection. Under proper conditions, the transplanted cells can develop into a functional tissue or organ.
- the patient may be administered with factors to induce the development of the cells. Such factors can be small molecule compounds, peptides, and nucleic acids. Examples include, but are not limited to, transforming growth factor ⁇ , bone morphogenic proteins, and nerve growth factor.
- the cells produced by the method of the present invention are also useful for studying development/differentiation mechanisms of embryos.
- the library is plated on two sets of replica filters.
- One set of filters (set A) is screened with cDNA made from uninduced cells.
- the other set of filters (set B) is screened with a comparable amount of cDNA made from induced cells.
- the cDNA used for screening the library can be labeled and visualized using methods well known in the art.
- These cDNAs encodes gene that are over-expressed in the induced cells.
- genes over-expressed in the uninduced pluripotent cells can be isolated.
- the pluripotent cells produced from non-human animals can be used to develop into organs or clones of the animals using the methods as described in, e.g., Campbell K. et al., Nature, 380: 64-66, 1996 . Accordingly, these cells are valuable for the pet and livestock industries, and can be used to preserve endangered animals.
- cells were fixed with 4% paraformaldehyde at 20°C for 10 minutes.
- cells were fixed with methanol at -20°C for 2 minutes and permeabilized with 0.1% Triton X-100 for 10 minutes.
- cells were fixed with 4% paraformaldehyde at 20°C for 10 minutes and permeabilized with 0.1% Triton X-100 for 10 minutes.
- the fixed cells were incubated for 30 minutes in a blocking solution containing phosphate-buffered saline (PBS), 1% bovine serum albumin (BSA), and 1% serum (Sigma, St. Louis, MO) from species same to the species in which the primary antibody was raised.
- PBS phosphate-buffered saline
- BSA bovine serum albumin
- serum Sigma, St. Louis, MO
- the cells were then incubated sequentially for 60 minutes each with primary antibodies properly diluted in the blocking solution, biotinylated anti-mouse secondary antibody, and strepavidin-conjugated horseradish peroxidase. Between each step, cells were washed with PBS containing 0.3% BSA for 10 minutes.
- the horseradish peroxidase activity was visualized by incubating with diaminobenzidine chromagen (Vector Laboratories Inc., CA). After the visualization, the cells were examined under a microscope, and pictures were taken.
- Mesenchymal stem cells were isolated from bone marrow and umbilical cord blood.
- Isolated mononuclear cells were seeded at a concentration of 1 x 10 6 cells/cm 2 in tissue culture dishes containing a regular medium, an alpha-modified minimum essential medium (MEM) with 20% ES cell-screened FBS (Hyclone, Logan, UT), 4 ng/ml b-FGF, 100 U/ml penicillin and 100ug/ml streptomycin (Invitrogen, Carlsbad, CA). After two weeks of culturing, many cells adhered to the culture dishes. These morphologically homogenous cells were self-renewing with a doubling time of 32-36 hours.
- MEM alpha-modified minimum essential medium
- the adherent cells were further characterized using immunocytochemistry staining as described above.
- Antibodies against CD34 or CD45 (cell surface antigens of heamatopoeitic lineage) were purchased from Bacton Dickinson (Mountain View, CA). The staining results revealed the cells were negative for CD34 and CD45, suggesting that the cells did not belong to heamatopoeitic lineage. Further, the cells could be induced to differentiate into osteocytes, chondrocytes and adipocytes using appropriate media according the methods described in, e.g., Pittenger M. et al., Science, 284:143-147, 1999 . Differentiated osteocytes were analyzed using von Kossa staining method.
- the isolated mesenchymal stem cells described above were cultured under a starving condition to generate pluripotent cells.
- the mesenchymal stem cells were cultured in the regular medium described in Example 2 for three to five passages. The cells were then placed in an alpha-modified MEM containing 0.5% FBS in the absence of b-FGF (a starving medium) for 5-7 days. Alternatively, the cells were maintained in the regular medium without changing the medium for two weeks. During the above starvation processes, the cells were monitored under a microscope daily, and no cell fusion was found. At the end of the starvation process, round and flattened colonies appeared in the cultures.
- mice feeder cells e.g., mitomycin-treated mouse STO cells (ATCC CRL-1503) or mouse embryonic fibroblast cells, in an Iscove's modified Dulbecco's medium (IMDM) with 20 % ES-screened FBS, 4 ng/ml bFGF, and 0.1 mM 2-mercaptoethanol.
- IMDM Iscove's modified Dulbecco's medium
- the cells were examined under a light microscope or a scanning electron microscope.
- a scanning electron microscopic examination the cells were cultured on a Melinex film (DuPont, Hopewell, VA), fixed in 2% Osmium tetroxide (w/v), 0.1M phosphate buffer pH 7.4 for 16 hours at 4°C and dehydrated through a graded ethanol series.
- the cells were examined under the field emission of a scanning electron microscope (SEM) Leo 982 (LEO Elektronenmikroskopie GmbH, Germany) operated at 2 kV. See, e.g., Bozzola J. et al., 1992.
- the cells were also characterized using immunocytochemistry staining as described above.
- Antibodies against SSEA-1 (MC-480, 1:50), SSEA-3 (MC-631, 1:50) and SSEA-4 (MC-813-70, 1:50) were obtained from Developmental Studies Hybridoma Bank, University o Iowa (Iowa city, IA).
- Anti-TRA-1-60 and anti-TRA- 1-81 antibodies were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA.). The results indicated that the cells were negative for SSEA-1 and positive for SSEA-3, SSEA-4, TRA-1-60, and TRA-1-81.
- the expression of transcription factor Oct-4 was also detected by reverse transcription-PCR as described in Reubinoff B. et al., Nature Biotechnol., 18:399-404, 2000 .
- the alkaline phosphatase activity of the cells was detected using a Sigma 86-R kit following the manufacture's instruction (Sigma, St. Louis, MO). The cells exhibited high level alkaline phosphatase activity. The cells were also examined for their telomerase activity using the TRAPeze ELSIA telomerase detection as described in Kim N. et al., Science, 266:2011-2015, 1994 . The results revealed a high-level telomerase activity in the cells.
- Karyotypes of the cells were determined using the method described in e.g., ISCN 1995: An International System for Human Cytogenetic Nomenclature (F. Mitelman, ed.) Karger, Basel (1995 ). Briefly, the cells were subcultured at a 1:4 dilution 12 hours before harvesting. The cells were collected with trypsin-EDTA and incubated with colcemid for 1.5 hours followed by lysis with hypotonic KCl and fixation in acid/alcohol. Metaphases were analyzed using methods as described by, e.g., Freshney, R in "Culture of animal cells-A manual of basic technique” 3rd edition. A John Wiley & Sons, Inc. New York (1994), pp 205-209 . The result revealed that the cells had all 46 chromosomes of human. The chromosomes had no noticeable alteration as compared to normal human chromosomes.
- the embryoid body-forming assay was performed to test the pluripotency of the cells prepared Example 3.
- the cells were cultured in non-coated bacteriologic Petri dishes for 4-6 days.
- the cells multiplied and formed spheroids (embryoid bodies) in suspension.
- the embryoid bodies were transferred and seeded onto chamber-slides coated with 0.1% gelatin.
- After one week in culture multiple clusters emerged from outgrowth of the spheroids.
- Each of the clusters displayed regular contraction and relaxation at 5-7 seconds per cycle for more than 12 hours.
- This mechanical activity was similar to that of a gut-like organ (primordial gut) developed from ES cells as described in Yamada T, et al., Stem Cells, 20:41-49, 2002 .
- the mesenchymal stem cells could not develop into embryoid bodies when they were induced under the same condition.
Abstract
Description
- Pluripotent embryonic stem (ES) cells are derived from early mammalian embryos. They can differentiate in vivo into all cell lineages, and, when induced in vitro, differentiate into most cell types. Due to their pluripotency, ES cells are believed to hold a great promise for treating degenerative or inherited diseases. Ethical considerations have hampered the use of human ES cells in research and therapy. Pluripotent cells of a non-embryonic origin (e.g., somatic cells) would circumvent this obstacle.
- It has been reported that some somatic cells can develop into cells of unrelated tissue types. However, their developmental potential is limited.
-
WO 02/34890 -
WO 01/21767 - There is a need for somatic cells that have unlimited developmental potential.
- The present invention produces a pluripotent animal cell that has a normal karyotype and is capable, when induced in vitro, of developing into an embryoid body, i.e., a cellular mass that can further develop into structures having features of an organ. Examples of such structures include a primordial gut, exhibiting regular contraction and relaxation. The cultured pluripotent cell is somatic since it is of a non-embryonic or non-germ-line origin.
- The invention is also capable of producing an animal cell that has a normal karyotype which is capable of, when introduced into a severely combined immunodeficient (SCID) mouse, developing into a teratoma. A teratoma is a tumor containing tissues derived from all three embryonic germ layers, i.e., ectoderm, mesoderm, and endoderm. Examples of the tissues include cornea lens and developing epidermis (ectoderm), cartilage and striated muscle (mesoderm), and liver and gastrointestinal tracts (endoderm). In one embodiment, the pluripotent cell, when induced in vitro, can develop into an embryoid body. The cultured cell does not express stage-specific embryonic antigen-1 (SSEA-1), i.e., SSEA-1 negative.
- Thus, in a first aspect, the present invention features a method of producing pluripotent animal cells, such as those described above. The method includes (1) culturing mesenchymal stem cells under a starving condition; and (2) identifying and enriching pluripotent cells among the cultured cells. The enriched pluripotent cells, when introduced into SCID mice, develop into teratomas, and do not express stage-specific embryonic antigen-1 (SSEA-1), i.e. SSEA-1 negative. The mesenchymal stem cells can be isolated from mammals, including a human. Any suitable tissues can be used to isolate mesenchymal stem cells for use in this method. Examples of such tissues include umbilical cord blood, bone marrow, amniotic fluid, adipose tissue, placenta, and peripheral blood.
- To produce pluripotent cells, the isolated cells are cultured under a starving condition unfavorable for cells to grow, e.g., in a starving medium containing 0.5% to 2% serum for 5-10 days, or in a regular medium containing 10% to 20% serum for 7 to 21 days without changing the medium. A regular medium contains nutrients and factors that promote cell proliferation. A starving medium is low in nutrients and factors for cell proliferation. The nutrients include serum and serum replacements, and the factors include insulin, epidermal growth factors (EGF), acidic fibroblast growth factors (aFGF), and basic fibroblast growth factors (bFGF). Among the cells cultured in a starving condition, pluripotent cells can be identified and enriched based on, for example, their morphology and cell-surface markers (e.g., SSEA-1 negative).
- It was unexpected that the pluripotent somatic cells of the invention can be produced under a starving condition. Other features or advantages of the present invention will be apparent from the following detailed description, and also from the claims.
- The present invention relates to culturing mesenchymal stem cells under a starving condition to produce pluripotent cells. These cells are pluripotent since they develop into embryoid bodies when induced in vitro, or develop into teratomas when introduced into SCID mice. The cells have all of the chromosomes, which are characteristic of those in normal cells, and have no noticeable alteration. In other words, they have a normal karyotype.
- The cells have phenotypes characteristic of undifferentiated ES cells. In one example, they spontaneously form flattened spheroid colonies in cultures. Similar colonies have been found in the culture of undifferentiated ES cells. See, e.g., Thomson J. et al., Science, 282:1145-1147, 1998. The cells can also show antigenic properties characteristic of undifferentiated ES cells, e.g., not expressing specific stage embryonic antigen (SSEA)-1, but expressing SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, and Oct-4. Oct is a family of transcription factors that are crucial for the development of pluripotent cells. Oct-4, specifically expressed in the mammalian germ line cells and stem cells, is essential for maintaining their pluripotency (see, e.g., Nichols J. et al., Cell, 95:379-391, 1998).
- The cells can also have high-level telomerase activity. A telomerase is a ribonucleoprotein that adds telomere repeats to the ends of chromosomes during cell duplication, thereby maintaining lengths of telomeres and chromosomes. High-level expression of telomerase has been found in germ line cells, ES cells, and embryonic tissues, but not in somatic cells. As a result, telomeres (and chromosomes) become shorter in somatic cells after each cell division. Finally, after a finite life span, somatic cells enter senescence due to loss of chromosomal DNA. As restored telomerase expression in somatic cells extends their life span, the high-level telomerase activity in cells produced by the invention suggests that their life span equals to that of ES cells.
- The method comprises culturing mesenchymal stem cells under a starving condition, and identifying and enriching the cultured cells. The pluripotent cells are, therefore, produced from mesenchymal stem cells which can be isolated from, e.g., umbilical cord blood, bone marrow, amniotic fluid, adipose tissue, placenta, or peripheral blood cells using the method described in Example 2 below or analogous methods well known in the art. See, e.g., Erices A. et al., British J. Haematol., 109:235-242, 2000, Pittenger M. et al., Science, 284:143-147, 1999, Safford K. et al., Biochem. Biophy. Research Comm., 294:371-379, 2002, and Erickson G. et al., Biochem. Biophy. Research Comm., 290:763-769, 2002. The mesenchymal stem cells can be maintained in an alpha-modified MEM containing 10-20% ES-screened fetal bovine serum (FBS) and bFGF, or cultured under a starving condition described above. Neither cell fusion nor nucleus transferring is required in converting the mesenchymal stem cells to pluripotent cells under the starving condition. After the starving process, pluripotent somatic cells can be identified according to their morphology (e.g., cell size and shape), enzymatic activity (e.g., alkaline phosphatase and telomerase), and surface makers (e.g., SSEA-1 negative, SSEA-3 positive, and SSEA-4 positive). The identified cells can be enriched using any suitable cell separation techniques known in the art. For example, as cells tend to form colonies, one can directly pick up the colonies using a micropipette under a microscope. To more rapidly enrich a large amount of cells, one can use the fluorescence-activated cell sorting (FACS) techniques. For example, anti-SSEA-3 monoclonal antibodies, anti-SSEA-4 monoclonal antibodies, and anti-SSEA-1 monoclonal antibodies linked with different fluorescent labels are used to enrich cells that are SSEA-3 positive, SSEA-4 positive, and SSEA-1 negative. These cells can be further examined for their pluripotency.
- One can test the pluripotency of the cells using any suitable methods. For example, one uses the in vivo teratoma-forming assay as described in Example 5 below. As a teratoma contains the derivatives of all three embryonic germ layers, the capacity of a cell to form a teratoma indicates that the cell is pluripotent. Alternatively, one can use the in vitro embryoid body-forming assay as described in Example 6 below. Formation of an embryoid body indicates that the cell is pluripotent.
- The cells produced by the method of the present invention can be used in a variety of ways. One can use the cells for treating degenerative or inherited diseases, avoiding ethical considerations of human embryo manipulation. To do so, one can isolate mesenchymal stem cells from a patient, e.g., lacking a functional gene essential for proper development of a tissue or organ. After producing pluripotent cells, he or she can introduce into the cells an expression nucleic acid vector encoding a functional version of the gene. The vector can be introduced into the cells via a variety of techniques, including calcium phosphate co-precipitation, DEAE-dextran-mediated transfection, lipofection, electroporation, microinjection, or virus-meditated techniques. Methods not affecting the pluripotency of the cells are preferred. Description of such techniques can be found in, e.g., United States Patent Application No.
5,591,625 and United States Patent Application NO.20020127715 . After delivering the functional gene into the cells, one can transplant the cells back into the patient using method known in the art. As the cells are produced from the patient, the treatment does not cause immune rejection. Under proper conditions, the transplanted cells can develop into a functional tissue or organ. To facilitate this development, the patient may be administered with factors to induce the development of the cells. Such factors can be small molecule compounds, peptides, and nucleic acids. Examples include, but are not limited to, transforming growth factor β, bone morphogenic proteins, and nerve growth factor. - The cells produced by the method of the present invention are also useful for studying development/differentiation mechanisms of embryos. One can identify conditions for inducing the development of pluripotent cells into a specific tissue or organ using such cells as a model system. Further, one can isolate genes that play roles during the development of embryos using differential cDNA screening as described in, e.g., Shen M. et al., Development, 124:429-42, 1997. One can prepare a cDNA library from the pluripotent cells that have been induced to develop, e.g., into the embryoid bodies described above. The library is plated on two sets of replica filters. One set of filters (set A) is screened with cDNA made from uninduced cells. The other set of filters (set B) is screened with a comparable amount of cDNA made from induced cells. The cDNA used for screening the library can be labeled and visualized using methods well known in the art. One can then select, from the library, cDNA clones displaying stronger hybridization signals on set B than on set A. These cDNAs encodes gene that are over-expressed in the induced cells. Vice versa, genes over-expressed in the uninduced pluripotent cells can be isolated. By the same token, one can also isolate genes over-expressed in cells before and after the above-described starving process. All of these isolated genes can be further studied to define their roles in respective processes.
- The pluripotent cells produced from non-human animals can be used to develop into organs or clones of the animals using the methods as described in, e.g., Campbell K. et al., Nature, 380: 64-66, 1996. Accordingly, these cells are valuable for the pet and livestock industries, and can be used to preserve endangered animals.
- The specific examples below are to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. Without further elaboration, it is believed that one skilled in the art can, based on the description herein, utilize the present invention to its fullest extent.
- Immunocytochemistry staining was performed to examine cell markers.
- For staining cell-surface markers, cells were fixed with 4% paraformaldehyde at 20°C for 10 minutes. For staining of cytoskeletal proteins, cells were fixed with methanol at -20°C for 2 minutes and permeabilized with 0.1% Triton X-100 for 10 minutes. For staining other intracellular molecules, cells were fixed with 4% paraformaldehyde at 20°C for 10 minutes and permeabilized with 0.1% Triton X-100 for 10 minutes.
- The fixed cells were incubated for 30 minutes in a blocking solution containing phosphate-buffered saline (PBS), 1% bovine serum albumin (BSA), and 1% serum (Sigma, St. Louis, MO) from species same to the species in which the primary antibody was raised. The cells were then incubated sequentially for 60 minutes each with primary antibodies properly diluted in the blocking solution, biotinylated anti-mouse secondary antibody, and strepavidin-conjugated horseradish peroxidase. Between each step, cells were washed with PBS containing 0.3% BSA for 10 minutes. The horseradish peroxidase activity was visualized by incubating with diaminobenzidine chromagen (Vector Laboratories Inc., CA). After the visualization, the cells were examined under a microscope, and pictures were taken.
- Mesenchymal stem cells were isolated from bone marrow and umbilical cord blood.
- Human bone marrow was purchased from BioWhittaker, Inc. (Walkersville, MD). Umbilical cord blood was obtained from subjects with noticed consent. To isolate mesenchymal stem cells, mononuclear cells were prepared from the human bone marrow or umbilical cord blood using Ficol-paque (d= 1.077 g/ml, Amersham Biosciences, Piscataway, NJ) density gradient method as described in, e.g., Erices A. et al., British J. Haematol., 109:235-242, 2000 or Pittenger M. et al., Science, 284:143-147, 1999.
- Isolated mononuclear cells were seeded at a concentration of 1 x 106 cells/cm2 in tissue culture dishes containing a regular medium, an alpha-modified minimum essential medium (MEM) with 20% ES cell-screened FBS (Hyclone, Logan, UT), 4 ng/ml b-FGF, 100 U/ml penicillin and 100ug/ml streptomycin (Invitrogen, Carlsbad, CA). After two weeks of culturing, many cells adhered to the culture dishes. These morphologically homogenous cells were self-renewing with a doubling time of 32-36 hours.
- The adherent cells were further characterized using immunocytochemistry staining as described above. Antibodies against CD34 or CD45 (cell surface antigens of heamatopoeitic lineage) were purchased from Bacton Dickinson (Mountain View, CA). The staining results revealed the cells were negative for CD34 and CD45, suggesting that the cells did not belong to heamatopoeitic lineage. Further, the cells could be induced to differentiate into osteocytes, chondrocytes and adipocytes using appropriate media according the methods described in, e.g., Pittenger M. et al., Science, 284:143-147, 1999. Differentiated osteocytes were analyzed using von Kossa staining method. Differentiated chondocytes were stained by Safranin O. Adipocytes were stained by Oil Red O. The above methods can be found in e.g., Colter D. et al., Proc. Natl. Acad. Sci. USA. 98: 7841-7845, 2001. These results indicated that the isolated cells were the mesenchymal stem cells (Prockop D. et al., Nature, 276:71-74, 1997.). Nonetheless, the developmental potential of these cells is limited since they could not develop into teratomas when introduced in SCID mice or into embryoid bodies when induced. See Examples 5 and 6 below.
- The isolated mesenchymal stem cells described above were cultured under a starving condition to generate pluripotent cells.
- The mesenchymal stem cells were cultured in the regular medium described in Example 2 for three to five passages. The cells were then placed in an alpha-modified MEM containing 0.5% FBS in the absence of b-FGF (a starving medium) for 5-7 days. Alternatively, the cells were maintained in the regular medium without changing the medium for two weeks. During the above starvation processes, the cells were monitored under a microscope daily, and no cell fusion was found. At the end of the starvation process, round and flattened colonies appeared in the cultures. Each of the colonies was picked using a micropipette and maintained in an undifferentiated state on mouse feeder cells, e.g., mitomycin-treated mouse STO cells (ATCC CRL-1503) or mouse embryonic fibroblast cells, in an Iscove's modified Dulbecco's medium (IMDM) with 20 % ES-screened FBS, 4 ng/ml bFGF, and 0.1 mM 2-mercaptoethanol. Cells from each colony could be maintained in the undifferentiated state and continue to proliferate for over four months (or more than 15 passages)
- Morphology, cell marker expression, enzymatic activity, and karyotypes of the cells from the colonies were examined.
- The cells were examined under a light microscope or a scanning electron microscope. For a scanning electron microscopic examination, the cells were cultured on a Melinex film (DuPont, Hopewell, VA), fixed in 2% Osmium tetroxide (w/v), 0.1M phosphate buffer pH 7.4 for 16 hours at 4°C and dehydrated through a graded ethanol series. After critical-point drying using liquid carbon dioxide and sputter coating with chromium, the cells were examined under the field emission of a scanning electron microscope (SEM) Leo 982 (LEO Elektronenmikroskopie GmbH, Germany) operated at 2 kV. See, e.g., Bozzola J. et al., 1992. Specimen preparation for scanning electron microscopy. In: Electron Microscopy: Principles and Techniques for Biologists. pp. 40-62. Jones and Bartlett Publishers, Boston. As the microscopic photographs indicated, the morphology of the cells was similar to that of undifferentiated ES cells, such as those described in Thomson J. et al., Science, 282:1145-1147, 1998.
- The cells were also characterized using immunocytochemistry staining as described above. Antibodies against SSEA-1 (MC-480, 1:50), SSEA-3 (MC-631, 1:50) and SSEA-4 (MC-813-70, 1:50) were obtained from Developmental Studies Hybridoma Bank, University o Iowa (Iowa city, IA). Anti-TRA-1-60 and anti-TRA- 1-81 antibodies were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA.). The results indicated that the cells were negative for SSEA-1 and positive for SSEA-3, SSEA-4, TRA-1-60, and TRA-1-81. The expression of transcription factor Oct-4 was also detected by reverse transcription-PCR as described in Reubinoff B. et al., Nature Biotechnol., 18:399-404, 2000.
- The alkaline phosphatase activity of the cells was detected using a Sigma 86-R kit following the manufacture's instruction (Sigma, St. Louis, MO). The cells exhibited high level alkaline phosphatase activity. The cells were also examined for their telomerase activity using the TRAPeze ELSIA telomerase detection as described in Kim N. et al., Science, 266:2011-2015, 1994. The results revealed a high-level telomerase activity in the cells.
- Karyotypes of the cells were determined using the method described in e.g., ISCN 1995: An International System for Human Cytogenetic Nomenclature (F. Mitelman, ed.) Karger, Basel (1995). Briefly, the cells were subcultured at a 1:4 dilution 12 hours before harvesting. The cells were collected with trypsin-EDTA and incubated with colcemid for 1.5 hours followed by lysis with hypotonic KCl and fixation in acid/alcohol. Metaphases were analyzed using methods as described by, e.g., Freshney, R in "Culture of animal cells-A manual of basic technique" 3rd edition. A John Wiley & Sons, Inc. New York (1994), pp 205-209. The result revealed that the cells had all 46 chromosomes of human. The chromosomes had no noticeable alteration as compared to normal human chromosomes.
- To test the pluripotency of the cells prepared as described in Example 3, the teratoma-forming assay was carried out.
- Approximately 1 x 105 cells were implanted into the hind leg musculature of SCID mice. Teratomas were observed 6-8 weeks after injection. The teratomas were harvested and subjected to histological examination using the method as described Thomson J. et al., Science, 282:1145-1147, 1998. All tumors examined contained tissues derived from all three embryonic germ layers: developing gastrointestinal tract (endoderm); cartilage, bone, and striated muscle (mesoderm); and cornea lens, fragmented keratin and developing epidermis (ectoderm). As a control, the mesenchymal stem cells described in Example 2 did not develop into teratomas in SCID mice.
- The embryoid body-forming assay was performed to test the pluripotency of the cells prepared Example 3.
- The cells were cultured in non-coated bacteriologic Petri dishes for 4-6 days. The cells multiplied and formed spheroids (embryoid bodies) in suspension. The embryoid bodies were transferred and seeded onto chamber-slides coated with 0.1% gelatin. After one week in culture, multiple clusters emerged from outgrowth of the spheroids. Each of the clusters displayed regular contraction and relaxation at 5-7 seconds per cycle for more than 12 hours. This mechanical activity was similar to that of a gut-like organ (primordial gut) developed from ES cells as described in Yamada T, et al., Stem Cells, 20:41-49, 2002. In contrast, the mesenchymal stem cells could not develop into embryoid bodies when they were induced under the same condition.
- All of the features disclosed in this specification may be combined in any combination. Each feature disclosed in this specification may be replaced by an alternative feature serving the same, equivalent, or similar purpose. Thus, unless expressly stated otherwise, each feature disclosed is only an example of a generic series of equivalent or similar features.
Claims (7)
- A method of producing pluripotent animal cells, the method comprising: culturing mesenchymal stem cells isolated from a tissue of an animal under a starving condition; and
identifying and enriching pluripotent cells among the cultured cells,
wherein the pluripotent cells, when introduced in a SCID mouse, develop into a teratoma and wherein the cells are stage-specific embryonic antigen-1 negative. - A method according to claim 1, wherein the animal is a mammal.
- A method according to claim 2, wherein the mammal is a human.
- A method according to any of claims 1-3, wherein the tissue is umbilical cord blood, bone marrow, amniotic fluid, adipose tissue, placenta, or peripheral blood.
- A method according to claim 4, wherein the tissue is umbilical cord blood, bone marrow, or amniotic fluid.
- A method according to any of claims 1 to 5, wherein the culturing step is performed by placing cells in a medium containing 0.5% to 2% serum for 5 to 10 days or in a medium containing 10% to 20% serum for 7 to 21 days without changing the medium.
- A method according to claim 6, wherein the culturing step is performed by placing cells in a medium containing 0.5% serum for 5-7 days or in a medium containing 20% serum for 2 weeks without changing the medium.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39888302P | 2002-07-26 | 2002-07-26 | |
US398883P | 2002-07-26 | ||
US287362 | 2002-11-04 | ||
US10/287,362 US7422736B2 (en) | 2002-07-26 | 2002-11-04 | Somatic pluripotent cells |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1384775A1 EP1384775A1 (en) | 2004-01-28 |
EP1384775B1 true EP1384775B1 (en) | 2009-03-25 |
Family
ID=30002798
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02257930A Expired - Lifetime EP1384775B1 (en) | 2002-07-26 | 2002-11-18 | Somatic pluripotent cells |
Country Status (12)
Country | Link |
---|---|
US (1) | US7422736B2 (en) |
EP (1) | EP1384775B1 (en) |
JP (1) | JP4685322B2 (en) |
KR (1) | KR100879079B1 (en) |
CN (1) | CN1470633B (en) |
AT (1) | ATE426661T1 (en) |
AU (1) | AU2002302089B2 (en) |
CA (1) | CA2413275C (en) |
DE (1) | DE60231708D1 (en) |
ES (1) | ES2322334T3 (en) |
SG (1) | SG129236A1 (en) |
TW (1) | TWI316962B (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8562973B2 (en) | 2010-04-08 | 2013-10-22 | Anthrogenesis Corporation | Treatment of sarcoidosis using placental stem cells |
US8728805B2 (en) | 2008-08-22 | 2014-05-20 | Anthrogenesis Corporation | Methods and compositions for treatment of bone defects with placental cell populations |
US8969315B2 (en) | 2010-12-31 | 2015-03-03 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory RNA molecules |
US9040035B2 (en) | 2011-06-01 | 2015-05-26 | Anthrogenesis Corporation | Treatment of pain using placental stem cells |
US9254302B2 (en) | 2010-04-07 | 2016-02-09 | Anthrogenesis Corporation | Angiogenesis using placental stem cells |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL156303A0 (en) * | 2000-12-06 | 2004-01-04 | Robert J Hariri | Method of collecting placental stem cells |
US20080152629A1 (en) * | 2000-12-06 | 2008-06-26 | James Edinger | Placental stem cell populations |
US7311905B2 (en) | 2002-02-13 | 2007-12-25 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
EP2316463B1 (en) | 2001-02-14 | 2017-04-12 | Anthrogenesis Corporation | Tissue matrices comprising placental stem cells, and methods of making them |
EP2314673B1 (en) * | 2001-02-14 | 2013-07-24 | Anthrogenesis Corporation | Post-partum mammalian placenta, its use and placental stem cells therefrom |
US7700090B2 (en) | 2002-02-13 | 2010-04-20 | Anthrogenesis Corporation | Co-culture of placental stem cells and stem cells from a second source |
KR20100125479A (en) * | 2002-11-26 | 2010-11-30 | 안트로제네시스 코포레이션 | Cytotherapeutics, cytotherapeutic units and methods for treatments using them |
US20040219136A1 (en) * | 2003-02-13 | 2004-11-04 | Hariri Robert J | Use of umbilical cord blood to treat individuals having a disease, disorder or condition |
GB0321337D0 (en) * | 2003-09-11 | 2003-10-15 | Massone Mobile Advertising Sys | Method and system for distributing advertisements |
WO2005047491A2 (en) * | 2003-11-10 | 2005-05-26 | Amgen Inc. | Methods of using g-csf mobilized c-kit+cells in the production of embryoid body-like cell clusters for tissue repair and in the treatment of cardiac myopathy |
AU2004296765B2 (en) * | 2003-12-02 | 2011-03-24 | Celgene Corporation | Methods and compositions for the treatment and management of hemoglobinopathy and anemia |
US7794704B2 (en) | 2004-01-23 | 2010-09-14 | Advanced Cell Technology, Inc. | Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration |
EP1708575A4 (en) * | 2004-01-23 | 2009-07-01 | Advanced Cell Tech Inc | Improved modalities for the treatment of degenerative diseases of the retina |
US20050186672A1 (en) * | 2004-01-27 | 2005-08-25 | Reliance Life Sciences Pvt. Ltd. | Tissue system with undifferentiated stem cells derived from corneal limbus |
US20060216821A1 (en) * | 2004-02-26 | 2006-09-28 | Reliance Life Sciences Pvt. Ltd. | Pluripotent embryonic-like stem cells derived from corneal limbus, methods of isolation and uses thereof |
AU2005220066B2 (en) * | 2004-02-26 | 2010-01-21 | Reliance Life Sciences Pvt. Ltd. | Pluripotent embryonic-like stem cells derived from corneal limbus, methods of isolation and uses thereof |
US8187875B2 (en) * | 2004-02-26 | 2012-05-29 | Reliance Life Sciences Pvt. Ltd. | Dopaminergic neurons derived from corneal limbus, methods of isolation and uses thereof |
MX343814B (en) | 2005-10-13 | 2016-11-24 | Anthrogenesis Corp | Immunomodulation using placental stem cells. |
KR100697326B1 (en) * | 2005-12-02 | 2007-03-20 | 재단법인서울대학교산학협력재단 | Multipotent Adult Stem Cells Having an Ability of Oct4 Expression Derived from Umbilical Cord Blood and Method for Preparing the Same |
JP4493045B2 (en) * | 2005-12-05 | 2010-06-30 | パナソニック株式会社 | Switching regulator circuit |
EP1974018A4 (en) * | 2005-12-08 | 2010-01-27 | Univ Louisville Res Found | Very small embryonic-like (vsel) stem cells and methods of isolating and using the same |
US9155762B2 (en) * | 2005-12-08 | 2015-10-13 | University Of Louisville Research Foundation, Inc. | Uses and isolation of stem cells from bone marrow |
EP2206724A1 (en) | 2005-12-13 | 2010-07-14 | Kyoto University | Nuclear reprogramming factor |
US8278104B2 (en) | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
US8129187B2 (en) | 2005-12-13 | 2012-03-06 | Kyoto University | Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2 |
PT2471905T (en) | 2005-12-29 | 2019-01-11 | Celularity Inc | Placental stem cell populations |
US20070280907A1 (en) * | 2006-04-07 | 2007-12-06 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Adult bone marrow cell transplantation to testes creation of transdifferentiated testes germ cells, leydig cells and sertoli cells |
KR20090031895A (en) * | 2006-06-09 | 2009-03-30 | 안트로제네시스 코포레이션 | Placental niche and use thereof to culture stem cells |
US7993918B2 (en) * | 2006-08-04 | 2011-08-09 | Anthrogenesis Corporation | Tumor suppression using placental stem cells |
WO2008051568A2 (en) | 2006-10-23 | 2008-05-02 | Anthrogenesis Corporation | Methods and compositions for treatment of bone defects with placental cell populations |
EP2129775A1 (en) | 2007-02-12 | 2009-12-09 | Anthrogenesis Corporation | Hepatocytes and chondrocytes from adherent placental stem cells; and cd34+, cd45- placental stem cell-enriched cell populations |
CN103356711A (en) | 2007-02-12 | 2013-10-23 | 人类起源公司 | Immunomodulation using placental stem cells |
US20100172830A1 (en) * | 2007-03-29 | 2010-07-08 | Cellx Inc. | Extraembryonic Tissue cells and method of use thereof |
US8574567B2 (en) | 2007-05-03 | 2013-11-05 | The Brigham And Women's Hospital, Inc. | Multipotent stem cells and uses thereof |
EP2607477B1 (en) | 2007-05-03 | 2020-09-23 | The Brigham and Women's Hospital, Inc. | Multipotent stem cells and uses thereof |
TWM322542U (en) * | 2007-05-23 | 2007-11-21 | Universal Scient Ind Co Ltd | Testing machine |
JP2008307007A (en) * | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | Human pluripotent stem cell induced from human tissue-originated undifferentiated stem cell after birth |
US9213999B2 (en) | 2007-06-15 | 2015-12-15 | Kyoto University | Providing iPSCs to a customer |
CN101978045A (en) * | 2007-09-26 | 2011-02-16 | 细胞基因细胞疗法公司 | Angiogenic cells from human placental perfusate |
ES2719931T3 (en) | 2007-09-28 | 2019-07-16 | Celularity Inc | Tumor suppression using human placental perfusate and intermediate natural killer cells that come from human placenta |
US20110104100A1 (en) * | 2007-10-04 | 2011-05-05 | Medistem Laboratories, Inc. | Compositions and methods of stem cell therapy for autism |
CN101878295A (en) * | 2007-10-12 | 2010-11-03 | 先进细胞技术公司 | Improved methods of producing RPE cells and compositions of RPE cells |
CN101978046A (en) * | 2007-10-30 | 2011-02-16 | 路易斯维尔大学研究基金会有限公司 | Uses and isolation of very small embryonic-like (vsel) stem cells |
KR20170116221A (en) * | 2007-11-07 | 2017-10-18 | 안트로제네시스 코포레이션 | Use of umbilical cord blood in the treatment of premature birth complications |
GB0805670D0 (en) * | 2008-03-28 | 2008-04-30 | Smith & Nephew | Increasing the plasticity of stem cells |
SG10201400329YA (en) | 2008-05-02 | 2014-05-29 | Univ Kyoto | Method of nuclear reprogramming |
JP5212977B2 (en) * | 2008-06-10 | 2013-06-19 | 国立大学法人福井大学 | Cancer stem cell enrichment method using low oxygen culture equipment and sugar-free medium |
JP5688970B2 (en) * | 2008-07-07 | 2015-03-25 | タカラバイオ株式会社 | Method for producing pluripotent stem cells |
CA2734237C (en) * | 2008-08-20 | 2019-07-02 | Anthrogenesis Corporation | Treatment of stroke using isolated placental cells |
WO2010021714A2 (en) * | 2008-08-20 | 2010-02-25 | Anthrogenesis Corporation | Improved cell composition and methods of making the same |
RU2015130665A (en) | 2008-11-19 | 2018-12-24 | Антродженезис Корпорейшн | AMNIOTIC ADHESIVE CELLS |
NZ592839A (en) * | 2008-11-21 | 2012-10-26 | Anthrogenesis Corp | Treatment of diseases, disorders or conditions of the lung using placental cells |
EP2387609B1 (en) | 2009-01-13 | 2018-05-16 | Stembios Technologies, Inc. | Non-embryonic stem cells and uses thereof |
WO2011063005A2 (en) | 2009-11-17 | 2011-05-26 | Advanced Cell Technology, Inc. | Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells |
WO2011069091A1 (en) | 2009-12-04 | 2011-06-09 | Boston Biomedical Research Institute, Inc. | Method for cloning pluripotent stem cells |
KR20120115602A (en) * | 2010-01-26 | 2012-10-18 | 안트로제네시스 코포레이션 | Treatment of bone-related cancers using placental stem cells |
JP2013530699A (en) | 2010-06-15 | 2013-08-01 | セルラー ダイナミクス インターナショナル, インコーポレイテッド | Overview of ready-made stem cell models for investigating biological responses |
JP5897002B2 (en) | 2010-07-07 | 2016-04-13 | セルラー ダイナミクス インターナショナル, インコーポレイテッド | Endothelial cell production by programming |
CN103097520B (en) | 2010-07-13 | 2017-12-05 | 人类起源公司 | The method for producing NK |
TWI542691B (en) | 2010-08-04 | 2016-07-21 | 幹細胞生物科技公司 | Somatic stem cells |
US9725689B2 (en) | 2010-10-08 | 2017-08-08 | Terumo Bct, Inc. | Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system |
JP6005666B2 (en) | 2011-02-08 | 2016-10-12 | セルラー ダイナミクス インターナショナル, インコーポレイテッド | Production of hematopoietic progenitor cells by programming |
US9925221B2 (en) | 2011-09-09 | 2018-03-27 | Celularity, Inc. | Treatment of amyotrophic lateral sclerosis using placental stem cells |
TWI571513B (en) | 2011-09-28 | 2017-02-21 | 幹細胞生物科技股份有限公司 | Somatic stem cells and method of preparing same |
AU2014215458A1 (en) | 2013-02-05 | 2015-08-13 | Anthrogenesis Corporation | Natural killer cells from placenta |
WO2014130770A1 (en) | 2013-02-22 | 2014-08-28 | Cellular Dynamics International, Inc. | Hepatocyte production via forward programming by combined genetic and chemical engineering |
EP2981605B1 (en) | 2013-04-03 | 2019-06-19 | FUJIFILM Cellular Dynamics, Inc. | Methods and compositions for culturing endoderm progenitor cells in suspension |
CN105992816B (en) | 2013-11-16 | 2018-04-17 | 泰尔茂比司特公司 | Cell amplification in bioreactor |
EP3122866B1 (en) | 2014-03-25 | 2019-11-20 | Terumo BCT, Inc. | Passive replacement of media |
WO2015164228A1 (en) | 2014-04-21 | 2015-10-29 | Cellular Dynamics International, Inc. | Hepatocyte production via forward programming by combined genetic and chemical engineering |
EP3198006B1 (en) | 2014-09-26 | 2021-03-24 | Terumo BCT, Inc. | Scheduled feed |
WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
US11312940B2 (en) | 2015-08-31 | 2022-04-26 | University Of Louisville Research Foundation, Inc. | Progenitor cells and methods for preparing and using the same |
WO2017152073A1 (en) | 2016-03-04 | 2017-09-08 | University Of Louisville Research Foundation, Inc. | Methods and compositions for ex vivo expansion of very small embryonic-like stem cells (vsels) |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
US11702634B2 (en) | 2017-03-31 | 2023-07-18 | Terumo Bct, Inc. | Expanding cells in a bioreactor |
CA3216719A1 (en) | 2021-05-03 | 2022-11-10 | Astellas Institute For Regenerative Medicine | Methods of generating mature corneal endothelial cells |
CN117716020A (en) | 2021-05-07 | 2024-03-15 | 安斯泰来再生医药协会 | Method for producing mature hepatocytes |
WO2024044134A1 (en) | 2022-08-23 | 2024-02-29 | Astellas Institute For Regenerative Medicine | Photoreceptor rescue cell (prc) compositions and methods for treatment of ocular disorders |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5453357A (en) * | 1992-10-08 | 1995-09-26 | Vanderbilt University | Pluripotential embryonic stem cells and methods of making same |
US5843780A (en) * | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
WO2002064748A2 (en) | 2001-02-14 | 2002-08-22 | Furcht Leo T | Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
EP2348104A1 (en) * | 1999-08-05 | 2011-07-27 | Mcl Llc | Multipotent adult stem cells and methods for isolation |
AU6400100A (en) | 1999-08-10 | 2001-03-05 | Dial Corporation, The | Transparent/translucent moisturizing/cosmetic/personal cleansing bar |
WO2001021767A2 (en) | 1999-09-24 | 2001-03-29 | Morphogen Pharmaceuticals, Inc. | Pluripotent embryonic-like stem cells, compositions, methods and uses thereof |
GB0026252D0 (en) | 2000-10-26 | 2000-12-13 | Univ Edinburgh | Pluripotential stem cells |
CA2434362A1 (en) | 2001-01-20 | 2002-07-25 | Cardion Ag | Pluripotent adult stem cells derived from regenerative tissue |
AU2002340897A1 (en) * | 2001-09-12 | 2003-03-24 | Develogen Aktiengesellschaft Fur Entwicklungsbiologische Forschung | A method for isolating, culturing and differentiating intestinal stem cells for therapeutic use |
-
2002
- 2002-11-04 US US10/287,362 patent/US7422736B2/en active Active
- 2002-11-18 EP EP02257930A patent/EP1384775B1/en not_active Expired - Lifetime
- 2002-11-18 ES ES02257930T patent/ES2322334T3/en not_active Expired - Lifetime
- 2002-11-18 DE DE60231708T patent/DE60231708D1/en not_active Expired - Lifetime
- 2002-11-18 AT AT02257930T patent/ATE426661T1/en not_active IP Right Cessation
- 2002-11-20 SG SG200207002A patent/SG129236A1/en unknown
- 2002-11-21 AU AU2002302089A patent/AU2002302089B2/en not_active Expired
- 2002-11-21 TW TW091133962A patent/TWI316962B/en not_active IP Right Cessation
- 2002-11-25 KR KR1020020073493A patent/KR100879079B1/en active IP Right Grant
- 2002-12-02 CA CA2413275A patent/CA2413275C/en not_active Expired - Lifetime
- 2002-12-16 JP JP2002363314A patent/JP4685322B2/en not_active Expired - Lifetime
-
2003
- 2003-01-08 CN CN031010377A patent/CN1470633B/en not_active Expired - Lifetime
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8728805B2 (en) | 2008-08-22 | 2014-05-20 | Anthrogenesis Corporation | Methods and compositions for treatment of bone defects with placental cell populations |
US9254302B2 (en) | 2010-04-07 | 2016-02-09 | Anthrogenesis Corporation | Angiogenesis using placental stem cells |
US8562973B2 (en) | 2010-04-08 | 2013-10-22 | Anthrogenesis Corporation | Treatment of sarcoidosis using placental stem cells |
US8969315B2 (en) | 2010-12-31 | 2015-03-03 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory RNA molecules |
US9040035B2 (en) | 2011-06-01 | 2015-05-26 | Anthrogenesis Corporation | Treatment of pain using placental stem cells |
Also Published As
Publication number | Publication date |
---|---|
US7422736B2 (en) | 2008-09-09 |
TWI316962B (en) | 2009-11-11 |
TW200401828A (en) | 2004-02-01 |
AU2002302089B2 (en) | 2008-08-14 |
CA2413275A1 (en) | 2004-01-26 |
SG129236A1 (en) | 2007-02-26 |
CA2413275C (en) | 2014-09-30 |
KR20040010029A (en) | 2004-01-31 |
JP4685322B2 (en) | 2011-05-18 |
EP1384775A1 (en) | 2004-01-28 |
CN1470633B (en) | 2010-09-29 |
AU2002302089A1 (en) | 2004-02-12 |
KR100879079B1 (en) | 2009-01-15 |
JP2004057198A (en) | 2004-02-26 |
US20040018617A1 (en) | 2004-01-29 |
DE60231708D1 (en) | 2009-05-07 |
ATE426661T1 (en) | 2009-04-15 |
ES2322334T3 (en) | 2009-06-19 |
CN1470633A (en) | 2004-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1384775B1 (en) | Somatic pluripotent cells | |
Zemelko et al. | Multipotent mesenchymal stem cells of desquamated endometrium: Isolation, characterization, and application as a feeder layer for maintenance of human embryonic stem cells | |
KR20080056181A (en) | Method of deriving progenitor cell line | |
WO2001053465A9 (en) | Human embryoid body-derived cells | |
US11236304B2 (en) | Method for differentiating induced pluripotent stem cells, which are prepared from endocardium-derived adult stem cells, into cardiovascular cells, and use thereof | |
CN104946590A (en) | Method for inducing Muse cells in adult bone marrow into neural precursor cells (NPCs) | |
US10080771B2 (en) | Compositions and methods for generation of human epithelial stem cells | |
US20150329827A1 (en) | Muse cells isolation and expansion | |
Toh et al. | Derivation of chondrogenic cells from human embryonic stem cells for cartilage tissue engineering | |
JP2021151269A (en) | Production method of pluripotent stem cell spheroid, method for expressing pluripotent stem cell marker and pluripotent stem cell spheroid | |
Chen et al. | Heterogeneity of stem cells in human amniotic fluid | |
KR101806401B1 (en) | Composition for inducing differentiation of induced pluripotent stem cell into mesenchymal stem cell and method for preparing mesenchymal stem cell using the same | |
Pall et al. | Establishment of an embryonic stem cell line from blastocyst stage mouse embryos | |
KR101177869B1 (en) | Multipotent Adult Stem Cells Having an Ability of Oct4 Expression Derived from Skin and Method for Preparing the Same | |
KR20050083106A (en) | Production method of human neural progenitor cell line from human embroyonic stem cells | |
US20140086882A1 (en) | Stem cell preparations and methods of use | |
KR100818216B1 (en) | Multipotent stem cell or cancer stem cell simultaneously expressing cripto-1 and oct4 derived from human adipose tissue or cancer and method for identifying the same | |
KR101631172B1 (en) | Method for culturing spermatogonial stem cells without feeder cells | |
TW200806794A (en) | Method of deriving pluripotent stem cells from a single blastomere | |
Aghami et al. | ESC cardiac differentiation and applications | |
Truong | Generation of Cardiomyocytes from Human Endogenous and Pluripotent Stem-Cell Derived Endothelial Cells | |
KR20140043260A (en) | Method for preparing avian somatic chimera by injection of bone marrow cell into fetilized egg |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
17P | Request for examination filed |
Effective date: 20040716 |
|
AKX | Designation fees paid |
Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR |
|
17Q | First examination report despatched |
Effective date: 20070227 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 60231708 Country of ref document: DE Date of ref document: 20090507 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2322334 Country of ref document: ES Kind code of ref document: T3 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090325 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090325 |
|
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090325 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090325 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090325 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090901 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090325 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090325 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090325 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090625 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20091229 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091130 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091130 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091130 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090626 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091118 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091118 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090325 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090325 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 14 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 15 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 16 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20210930 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20210930 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20211207 Year of fee payment: 20 Ref country code: SE Payment date: 20211012 Year of fee payment: 20 Ref country code: DE Payment date: 20210923 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20211012 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 60231708 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20221125 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20221117 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20221117 Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20221119 |